Innate Pharma (IPHYF) Net Income (2019 - 2025)
Historic Net Income for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to -$25.6 million.
- Innate Pharma's Net Income rose 193.0% to -$25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$106.5 million, marking a year-over-year decrease of 23635.95%. This contributed to the annual value of -$133652.4 for FY2022, which is 9840.63% up from last year.
- According to the latest figures from Q2 2025, Innate Pharma's Net Income is -$25.6 million, which was up 193.0% from -$48.6 million recorded in Q4 2024.
- Innate Pharma's 5-year Net Income high stood at $7.5 million for Q2 2021, and its period low was -$48.6 million during Q4 2024.
- For the 5-year period, Innate Pharma's Net Income averaged around -$11.9 million, with its median value being -$6.2 million (2023).
- Examining YoY changes over the last 5 years, Innate Pharma's Net Income showed a top increase of 89402.78% in 2023 and a maximum decrease of 461673871.47% in 2023.
- Innate Pharma's Net Income (Quarter) stood at -$8.4 million in 2021, then soared by 100.0% to -$133.65 in 2022, then tumbled by 4616738.71% to -$6.2 million in 2023, then tumbled by 687.89% to -$48.6 million in 2024, then soared by 47.32% to -$25.6 million in 2025.
- Its Net Income stands at -$25.6 million for Q2 2025, versus -$48.6 million for Q4 2024 and -$26.1 million for Q2 2024.